GPhA Eyeing Alternative Terms For "Follow-On" Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
The generic industry trade group hopes to reach consensus on nomenclature in time for an FDA/DIA workshop on follow-on proteins in February. GPhA opposes use of the terms "follow-on," "biosimilar" and "biocomparable."
You may also be interested in...
FDA Will Release Follow-On Biologics Background Document By Year-End
The document will illustrate prior regulatory treatment paths for natural source-derived and biotech protein products, so it should not cause any controversy, Acting Commissioner for Operations Woodcock says.
Generic Biologics Provide Significant Growth Opportunity, Barr Says
Barr plans to limit its biotech projects to four until a regulatory pathway for follow-on biologics is established, CEO Downey says. The generic industry is arguing for “common sense” rules, he asserts.
FDA Will Release Follow-On Biologics Background Document By Year-End
The document will illustrate prior regulatory treatment paths for natural source-derived and biotech protein products, so it should not cause any controversy, Acting Commissioner for Operations Woodcock says.